Physician profile
Wen Young
NPI 1427008861
$746.43
in general payments reported to CMS, 2019-2025
9 companies · $405 in 2025
The $405 reported for 2025 was more than what 77% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $286 · 2024: $55.09 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.18 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $273.52 | 2023-2025 | Pylarify |
| Telix Pharmaceuticals | $148.80 | 2025 | Illuccix |
| Bayer Healthcare Pharmaceuticals INC. | $92.45 | 2023-2024 | |
| Pfizer INC. | $58.56 | 2024-2025 | |
| Ge Healthcare | $44.34 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $43.25 | 2025 | Enhertu |
| Life Molecular Imaging Ltd | $41.00 | 2023 | Neuraceq |
| Siemens Medical Solutions USA, INC. | $26.01 | 2025 | Naeotom Alpha, Luminos Q.Namix T, Symbia Pro.Specta Q3 |
| Blue Earth Diagnostics | $18.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wen Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.